Elevated pretreatment blood pressure and IV thrombolysis in stroke

Objectives: We investigated whether an active blood pressure–lowering strategy is associated with more patients receiving thrombolytics compared with a conservative “watch and measure” strategy, and assessed safety and functional outcome of these 2 treatment strategies. Methods: This is a post hoc analysis in 2 randomized controlled stroke trials, the PRACTISE (Promoting Acute Thrombolysis in Ischemic Stroke) and the PASS (Preventive Antibiotics in Stroke Study). We included all patients with elevated pretreatment blood pressure above 185/110 mm Hg at presentation but otherwise eligible for IV thrombolysis (IVT). The decision to use an active or conservative strategy was in accordance with local hospital treatment guidelines. The primary outcome was the proportion of patients treated with IVT. Secondary outcomes were (1) symptomatic intracranial hemorrhage (increased neurologic deficit with a concomitant hemorrhage on neuroimaging), (2) functional outcome at 3 months, and (3) the door-to-needle time. Results: We included 224 patients, 66 (29%) received the active and 158 (71%) the conservative strategy. In the active group, 55 patients (83%) received thrombolytics vs 87 (55%) in the conservative group, an increase of 28% (95% confidence interval: 16%–40%). If only patients actually treated with IVT were considered, the rate of symptomatic intracranial hemorrhage was 7% in both groups. There was no difference in door-to-needle time. Conclusions: Active blood pressure lowering was associated with an increased proportion of patients treated with IVT compared with a conservative strategy, without a difference in symptomatic hemorrhage rate.

[1]  Christopher S Coffey,et al.  2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[2]  M. Limburg,et al.  Variation in Clinical Practice of Intravenous Thrombolysis in Stroke in the Netherlands , 2013, Cerebrovascular Diseases Extra.

[3]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[4]  Peter Sandercock,et al.  Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies , 2012, Stroke.

[5]  C. Anderson,et al.  Blood pressure lowering in acute phase of stroke: latest evidence and clinical implications , 2012, Therapeutic advances in chronic disease.

[6]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[7]  W. Hacke,et al.  Frequency of Increased Blood Pressure Levels During Systemic Thrombolysis and Risk of Intracerebral Hemorrhage , 2011, Stroke.

[8]  Robbert Huijsman,et al.  Promoting Thrombolysis in Acute Ischemic Stroke , 2011, Stroke.

[9]  P. Nederkoorn,et al.  Preventive Antibiotics in Stroke Study: Rationale and Protocol for a Randomised Trial , 2011, International journal of stroke : official journal of the International Stroke Society.

[10]  W. Owens Blood Pressure Control in Acute Cerebrovascular Disease , 2011, Journal of clinical hypertension.

[11]  A. Alexandrov,et al.  Pre–Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage , 2009, Stroke.

[12]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[13]  J. Grotta,et al.  Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke. , 2008, Archives of neurology.

[14]  Gary A. Ford,et al.  Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.

[15]  A. Alexandrov,et al.  Association of Pretreatment Blood Pressure With Tissue Plasminogen Activator-Induced Arterial Recanalization in Acute Ischemic Stroke , 2007, Stroke.

[16]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[17]  Ching-Kuan Liu,et al.  Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke , 2006, Cerebrovascular Diseases.

[18]  Michael D. Hill,et al.  Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study , 2005, Canadian Medical Association Journal.

[19]  Joseph P Broderick,et al.  Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.

[20]  J. Grotta,et al.  Hypertension and its treatment in the NINDS rt-PA Stroke Trial. , 1998, Stroke.

[21]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[22]  J. Broderick,et al.  Factors Related to Intracranial Hematoma Formation in Patients Receiving Tissue‐Type Plasminogen Activator forAcute Ischemic Stroke , 1994, Stroke.

[23]  J. Marler,et al.  Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.

[24]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.